Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shocking therapy may keep cancer patients on their feet

NCT ID NCT04364256

Symptom relief Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether neuromuscular electrical stimulation (NMES) can help Veterans with blood cancers maintain physical function and reduce fatigue during stem cell transplant. 46 participants used NMES while in the hospital. The goal was to see if this approach could prevent muscle loss and improve quality of life compared to usual care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

46 people

The number who actually took part.

Started

May 2021

Finished

Dec 2025

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * adequate cognitive and language ability to provide consent * Veteran enrolled in MTU at VAPSHCS for planned standard of care autologous HCT Exclusion Criteria: * active deep vein thrombosis or thrombophlebitis * untreated hemorrhagic disorders * concomitant study inclusion in other nutritional or physical exercise interventional trials * concomitant use of anabolic agents * rhabdomyolysis or other muscle conditions where NMES is contraindicated * implanted cardiac device * baseline patient-reported muscle soreness of 5-6 on the soreness likert scale that is unrelated to recent physical exertion * history of prior hematologic stem cell transplant * probable or definitive liver cirrhosis * reduced renal clearance defined as Stage 4 chronic kidney disease (glomerular filtration rate \<45 ml/min/1.73 m2)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autologous hematopoietic stem cell transplant are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm lymphoma muscular atrophy plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autologous hematopoietic stem cell transplant

Contacts and locations

Locations

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA

    Seattle, Washington, 98108-1532, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.